malignant/atypical meningioma
Conditions
Interventions
1) The patient is over 20 year old, who has grade 2 or 3 recurrent meningioma, or is diagnosed with grade 2 or 3 meningioma in initial surgery and need additional resection. 2) A single intrave
Sponsors
Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Hospital inpatients over the age of 20 years (2) Patients who are diagnosed as primary or recurrent malignant meningioma (WHO grade 2 or 3), which needs resection. (3) The tumor will be able to be subtotally removed. (4) Residual tumor region will be able to be irradiated by laser. (5) Laser irradiation site do not include large cerebral arteries. (6) KPS>=60% (7) Organ Function: 1. WBC>= 3,000 /micro L 2. Hb>=8.0 g/dL 3. Plt>=100,000 /micro L 4. AST (GOT) <=100 IU/L 5. ALT (GPT) <=100 IU/L 6. serum Cr <= 1.5 mg/dL (8) Patients willing to participate in the trial and sign written informed consent
Exclusion criteria
Exclusion criteria: (1) Subject is known, suspected or has history of intolerance or allergy to Talaporfin Sodium. (2) Subjects with porphyria. (3) Severe liver and renal dysfunction. (4) Subject with allergies such as a drug hypersensitivity constitution. (5) Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study, as risks of fetal and teratogenic adverse effects of Talaporfin Sodiumare not known.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free time of the laser irradiation site | — |
Countries
Japan
Contacts
Public ContactSASAYAMA TAKASHI
Kobe University Hospital Neurosurgery
Outcome results
None listed